Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment

NCT01076842 on ClinicalTrials.gov · last registry update 2011-06-27

Finished April 2011, after enrolling 75 people. Primary outcome, as filed: The primary endpoint is the improvement in A1C goal measured in mean reduction in A1c levels over 24 weeks. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 75
Started: 2008-04
Primary completion: 2011-04 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The primary endpoint is the improvement in A1C goal measured in mean reduction in A1c levels over 24 weeks.

Conditions studied

Diabetes Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.